Rare cancers, exceptional responses and an expansion roadmap
How a collaborative immunotherapy clinical trial is providing access to life saving treatments for patients with rare cancers across Victoria and beyond.
Collectively, rare cancers are not so rare, representing 20-25 per cent of all cancer diagnoses. Overall treatment outcomes for patients tend to be poor and survival is inferior compared to patients with common malignancies.
A highly successful combination immunotherapy clinical trial for patients with rare cancers is really making an impact on these statistics - and saving lives.
The ONJ2016-001 trial enrolled 120 patients into three ‘baskets’ - rare upper gastrointestinal, rare neuroendocrine and rare gynaecological cancers at five clinical sites: Austin Health, Peter MacCallum Cancer Centre, Monash Health, Border Medical Oncology and Blacktown Hospital.
To mark International Clinical Trials Day 2021, join us to hear from this outstanding collaborative trial team. The team will describe the exceptional responses observed across the baskets and plans to expand the study to urban, regional and rural Australian sites, incorporating genomic testing and teletrials, to improve access to life saving treatments for patients with rare cancers across the state and the country, starting with a major new program through Bendigo Health.
#Overcomingcancertogether #ICTD2021 #rarecancers #Immunotherapy #regionaltrials
Prof Jonathan Cebon, Head, Cancer Immunobiology Program, Olivia Newton-John Cancer Research Institute
Dr Oliver Klein, Clinician Scientist, Cancer Immunobiology Program, Medical Oncologist, Olivia Newton-John Cancer Research Institute
Trial participant, Pauline T.
Dr Craig Underhill, Clinical Director of Oncology Services at Albury Wodonga Health, Clinical Director of Hume Regional Integrated Cancer Services, VCCC alliance Regional Oncology Lead
Dr Sam Harris, Medical Oncologist, Bendigo Health
Monday 24 May